1256337-02-6

Usage

Uses

Used in Medicinal Chemistry:
(6-tert-Butoxycarbonylamino-pyridin-3-yl)-acetic acid is used as a building block for the synthesis of novel bioactive compounds due to its unique structural features, which can be exploited to create new pharmaceutical drugs.
Used in Drug Discovery and Development:
In the pharmaceutical industry, (6-tert-Butoxycarbonylamino-pyridin-3-yl)-acetic acid is used as a valuable tool for exploring structure-activity relationships. This helps in designing new drug candidates with improved efficacy and selectivity.
Used in Research and Development:
Academic and industrial research laboratories utilize (6-tert-Butoxycarbonylamino-pyridin-3-yl)-acetic acid for studying its potential pharmacological or biological activities. This can lead to a better understanding of its applications and the development of new therapeutic strategies.

Upstream product

• 197376-47-9 ethyl (6-chloro-pyridin-3-yl)acetate 
• 70258-18-3 2-chloro-5-(chloromethyl)pyridine 
• 39891-09-3 (6-chloro-pyridin-3-yl)-acetonitrile 
• 1256337-01-5 ethyl (6-tert-butoxycarbonylaminopyridin-3-yl)acetate 

Relevant academic research and scientific papers

Triple-helical recognition of RNA using 2-aminopyridine-modified PNA at physiologically relevant conditions

Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases form stable and sequence-selective triple helices with double-stranded RNA at physiologically relevant conditions. The M-modified PNA showed unique RNA selectivity by having tw

COMPOSITIONS AND METHODS FOR RECOGNITION OF RNA USING TRIPLE HELICAL PEPTIDE NUCLEIC ACIDS

Peptide nucleic acids containing thymidine and 2-aminopyridine (M) nucleobases formed stable and sequence selective triple helices with double stranded RNA at physiologically relevant conditions. The M-modified PNA displayed unique RNA selectivity by having two orders of magnitude higher affinity for the double stranded RNAs than for the same DNA sequences. Preliminary results suggested that nucleobase-modified PNA could bind and recognize double helical precursors of microRNAs.

BETA-LACTAMASE INHIBITORS

Disclosed herein are α-aminoboronic acids and their derivatives which act as inhibitors of beta-lactamases. Also disclosed herein are pharmaceutical compositions comprising α-aminoboronic acids and methods of use thereof.